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Background: Cure rate of early Hodgkin Lymphoma are high and avoidance of late toxicities is of paramount
importance. This comparative study aims to assess the normal tissue sparing capability of intensity-modulated
radiation therapy (IMRT) versus standard three-dimensional conformal radiotherapy (3D-CRT) in terms of
dose-volume parameters and normal tissue complication probability (NTCP) for different organs at risk in
supradiaphragmatic Hodgkin Lymphoma (HL) patients.
Methods: Ten HL patients were actually treated with 3D-CRT and all treatments were then re-planned with IMRT.
Dose-volume parameters for thyroid, oesophagus, heart, coronary arteries, lung, spinal cord and breast were
evaluated. Dose-volume histograms generated by TPS were analyzed to predict the NTCP for the considered organs
at risk, according to different endpoints.
Results: Regarding dose-volume parameters no statistically significant differences were recorded for heart and
origin of coronary arteries. We recorded statistically significant lower V30 with IMRT for oesophagus (6.42 vs 0.33,
p = 0.02) and lungs (4.7 vs 0.1 p = 0.014 for the left lung and 2.59 vs 0.1 p = 0.017 for the right lung) and lower V20
for spinal cord (17.8 vs 7.2 p = 0.02). Moreover the maximum dose to the spinal cord was lower with IMRT
(30.2 vs 19.9, p <0.001). Higher V10 with IMRT for thyroid (64.8 vs 95, p = 0.0019) and V5 for lungs (30.3 vs 44.8,
p = 0.03, for right lung and 28.9 vs 48.1, p = 0.001 for left lung) were found, respectively. Higher V5 and V10 for
breasts were found with IMRT (V5: 4.14 vs 20.6, p = 0.018 for left breast and 3.3 vs 17, p = 0.059 for right breast;
V10: 2.5 vs 13.6 p = 0.035 for left breast and 1.7 vs 11, p = 0.07 for the right breast.) As for the NTCP, our data point
out that IMRT is not always likely to significantly increase the NTCP to OARs.
Conclusions: In HL male patients IMRT seems feasible and accurate while for women HL patients IMRT should be
used with caution.
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distribution, and reproduction in any mediumDifferent studies indicate that long-term HL survivors
experience treatment-related morbidity that impairs thy-
roid, pulmonary and cardiovascular function [1]. Previ-
ous works have shown that the irradiation of the thyroid
region is likely to induce 50% risk of developing hypo-
thyroidism and a 20% risk of developing thyroid nodules
[2, 3]. Other authors observed late pulmonary and car-
diac toxicity when these organs are irradiated at a given
dose level [4, 5]. In particular, prospective data with
long-term follow-up showed that young patients treated
with mediastinal radiotherapy for Hodgkin lymphomatral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
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life [6].
Furthermore, for female HL survivors, breast cancer is
the most common second malignancy [7], and several
studies have demonstrated that women treated with
radiotherapy for Hodgkin's lymphoma (HL) have an ele-
vated risk of developing breast cancer compared with
the general population [8, 9].
Currently, Involved Field Radiation Therapy (IFRT) is
considered the standard of care in early stage HL, mainly
delivered with three-dimensional conformal radiation
therapy (3D-CRT) at mean dose of 30 Gy. Nevertheless,
even with IFRT 3D-CRT large treatment volumes may
be necessary to encompass more than 2 involved lym-
phonodal regions and/or bulky lesion, with an irradi-
ation of a large volume of normal tissue. Regarding the
long-term toxicity, a dose reduction to organ at risk can
be obtained either by lowering the total delivered dose
or by reducing the treatment volume. Recently a ran-
domized study by German Hodgkin Study Group has
shown a good local control with 20 Gy in low-risk early
stage HL [10]. Regarding the target radiation volume, in
the on-going EORTC-GELA H10 trial, a further reduc-
tion of the target radiation volume was employed using
Involved Nodal Radiation Therapy (INRT) [11].
There is growing dosimetric evidence that highly con-
formal irradiation modalities may improve critical organs
sparing in the treatment of lymphoma involving large
mediastinal disease volumes, with clinically relevant con-
sequences [12]. Recently, IMRT was employed in HL pa-
tients with the aim of reducing the radiation dose to
lung, hearth, thyroid, spinal cord and breast [13-19].
Goodman et al. [13] showed that compared to con-
ventional parallel-opposed plans and conformal radio-
therapy plans, IMRT could decrease the dose delivered
to the lung by 12% and 14%, meanwhile increasing the
PTV coverage. In a recent study the normal tissue
sparing capability of IMRT in the treatment of Hodgkin'sTable 1 Patients, disease and treatment planning characterist
Patient Age Gender Disease stage
1 21 F IIB Bulky
2 21 F IIA
3 53 F IIA
4 43 M IIA
5 13 M IIA
6 28 M IIA
7 33 F IIA
8 17 M IIB
9 34 F IIA
10 38 M IIB Bulkylymphoma was studied. The authors concluded that the
forward planned IMRT technique could be easily used
for improving PTV conformity while sparing [18].
In the present study we compared the actually 3D-CRT
delivered treatment with a simulated IMRT plan in 10
patients with diagnosis of early stage HL, to report about
the feasibility and toxicity of IMRT technique in this
setting of patients. The normal tissue complication prob-
ability (NTCP), evaluated from dose volume histograms
(DVHs), was calculated both for 3D-CRT and IMRT plans
with the aim of assessing the organs at risk sparing cap-
ability of the two dose delivery technique.
Methods
Patients
Ten patients (5 male and 5 female) with diagnosis of supra-
diaphragmatic HL were enrolled and selected for a com-
parativedosimetricevaluationbetween3D-CRTandIMRT.
All patients underwent pre-chemotherapy FDG-PET/
CT imaging and total body CT with iodine intravenous
contrast injection. Chemotherapy was administered in 9
patients according to ABVD protocol while in 1 case
COOP-ABV protocol was employed because of the
young age of the patient [20, 21]. All patients were trea-
ted with combined therapy consisting in chemotherapy
and 3D-CRT according to Involved Field Radiation Ther-
apy (IFRT) volume with a standard fractionation scheme
of 2 Gy × 15 fractions. All patients actually treated with
3D-CRT were replanned with IMRT (5 fields techni-
ques) as if the patients should be really treated and dosi-
metric outcomes of the IMRT treatment plans were
compared with standard 3D-CRT plans. Toxicities were
recorded and graded according to RTOG criteria [22]. Pa-
tients and disease characteristics are shown in Table 1.
Volume definition
Target contouring was determined by the pre-chemotherapy
imaging (CTand or PET/CT-based). CTV was assumed toics
RT Dose PTV Volume Fields
(cm3) 3D-CRT IMRT
30 Gy 831 2 5
30 Gy 323 4 5
30 Gy 553 5 5
30 Gy 841 5 5
30 Gy 231 2 5
30 Gy 684 6 5
30 Gy 260 4 5
30 Gy 349 6 5
30 Gy 497 2 5
30 Gy 642 2 5
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nodes before chemotherapy. Contouring was performed
by an experienced radiation oncologist according to
GHSG guidelines [23]. PTV was determined adding a
three-dimensional 10-mm isotropic margin to the CTV,
according to IFRT volume definitions.
Treatment planning
Treatment planning was performed for all patients with
CT scanning with 2-mm slice thickness. Contouring and
planning were performed with Varian Eclipse treatment
planning system (TPS version 8.6, Varian Systems, Palo
Alto, CA). Two different immobilization devices were
used (5 patients were treated with wing-board and 5
patients with mask). For 3D-CRT planning, a coplanar
mono-isocentric single and half-field technique was used
for treatment plans, according to target geometry and
volume size. Two different beam configurations were
used: a pair of parallel-opposed beams (antero-posterior
and postero-anterior) in 4 patients, and a multi-fields
(4 to 6) irradiation technique with half-field technique
in 6 patients. In both cases, a multi leaf collimator was
used with a 0.5 cm uniform margin around the PTV.
For all patients, the prescribed dose was 30 Gy to the
PTV with a dose homogeneity of 5% and 7%, as recom-
mended by the International Commission on Radiation
Units and Measurements Report No. 50 [24]. Treat-
ments were performed with a 6 MV photon beam from
Varian Clinac DHX equipped with a 120 leaf Millennium
Multileaf collimator.
Treatment plans with IMRT were performed main-
taining the same target coverage and applying the same
dose scheme of 2 Gy × 15. The actual 3D-CRT plans
were retrieved and replanned for the IMRT study using
the same treatment planning system. This system uses a
gradient-search based inverse planning algorithm to gen-
erate optimal beam fluences, for which planners specify
the dose objectives/constraints for the target and all
other normal structures. The goal of the optimization in
the present study was to minimize an objective function
as defined on the basis of the difference between the
desired and calculated doses for the target and all speci-
fied critical organs.
All IMRT plans were designed with five equally spaced
beams centered on the target volume (gantry angles at 0°,
72°, 144°, 216°, and 288°). All plans were designed and
calculated with sliding window radiation delivery
technique.
Plan comparison
We computed the target coverage as measured by the
volume fraction of the target receiving at least 95% of
the prescription dose of the PTV (V95), the dose cover-
ing at least 95% of the PTV (D95%) and the maximal,minimal and mean PTV dose. The V2, V5, V10, V20 and
V30 parameters for the origin of coronary arteries and
heart, the V5, V10, V20 and V30 for spinal cord and breast
(breast for female patients only) and V5,V10,V20 and V30
for lung, thyroid, oesophagus were calculated for both
techniques and then compared. All these parameters were
retrieved from differential DVHs.
NTCP calculation
In order to assess the normal tissue sparing capability of
both radiation treatment techniques, normal tissue com-
plication probabilities (NTCPs) for lungs, heart, spinal
cord, oesophagus and thyroid were calculated for each
patient using a custom MATLAB based code. Only for
women, breast NTCP was also evaluated. The dose-
volume histogram (DVH) reduction algorithm of Lyman
and Wolbarst [25] and the effective volume method
introduced by Kutcher et al. [26] were applied to each
DVH to produce a value for the NTCP. In this model,
the organ dose is described as independent fractional
volume elements vi (such that
P
i
vi ¼ 1 ), irradiated to
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where TD50 is the tolerance dose for 50% complications
for uniform whole organ irradiation and dref the refer-




where Vref is the total volume of the organ, Vi the vol-
ume fraction, The parameter m in Eq. 2 is the slope fac-
tor which affects the steepness of the S-shaped dose-
response curve, while n is the parameter which represents
the volume effect. Parameters for NTCP calculations
(volume effect n, slope m, and tolerance doses TD50 and
TD5) were taken from Burman et al. [27] and are shown
in Table 2. For each organ at risk (OAR), the different
end point is also reported. Given the low doses received
by the critical organs, we calculated NTCP correspond-
ing to TD5/5 (tolerance doses leading to 5% complication
Table 2 Parameters for NTCP calculation
Organ Size Factor (n) Slope (m) TD5/5 TD50/5 End Point
Lung 0.87 0.18 24.5 Pneumonities
Heart 0.35 0.10 40 Pericardities
Spinal cord 0.05 0.175 47 Myelities/necrosis
Thyroid 0.22 0.26 45 Thyroidities
Oesophagus 0.06 0.11 55 Clinical stricture/perforation
Breast 0.78 0.27 62.5 Fibrosis
Abbreviations: TD5/5 = tolerance doses leading to 5% complication rates at 5 years, TD50/5 = tolerance doses leading to 50% complication rates at 5 years.
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where the TD50/5 (tolerance doses leading to 50% compli-
cation rates) was calculated.
Statistical analysis
Analyses were performed using a paired two-tailed Stu-
dent t test to determine if there was a significant differ-
ence between all the parameters obtained with 3D-CRT
and IMRT. Differences were considered statistically sig-
nificant at p ≤ 0.05. Statistical analysis was performed
with Origin Pro 8.5 package (OriginLab Corporation,
Northampton USA).
Results
All ten patients completed their prescribed therapeutic
schedule. The radiation treatment started at a median of
50 days (range 31-73) from the end of chemotherapy.
During radiation therapy, no acute toxicity was recorded
in 5 patients, while 4 patients presented dysphagia G1-
G2 and 1 patient presented dysphagia G1 and erythema
G1. All patients were in complete response at the re-
stanging after radiation therapy and no relapses were
recorded after a median follow-up of 34 months (range
24-48). No late toxicities were recorded.
PTV coverage
As shown in Table 3, the D95 was better with IMRT re-
spect to 3D-CRT with statistically significant differences
(p = 0.028) while no statistically significant difference
was recorded for V95 between the two techniques. For
all patients, the mean dose to the target volume was
similar for both treatments. The minimum dose wasTable 3 Comparison between PTV dose parameters of 3D-CRT
Parameter 3D-CRT
Dose minimum (%) 41.4 (23.3 - 65.2)
Dose maximum (%) 108.8 (105.2 – 112.6)
Dose mean (%) 100.7 (98.2 – 103.8)
Dose median (%) 101.4 (99.4 – 103.8)
V95 (%) 29.2 (13.9 - 47.0)
D95 (%) 27.7 (25.2 – 29.5)significantly higher for IMRT, while the maximum dose
and the median dose were significantly higher for 3D-
CRT (Figure 1).Dose to thyroid
The mean thyroid dose was 15.25 Gy with 3D technique
compared to 21.4 Gy with IMRT, with a statistically sig-
nificant difference (p = 0.02). The minimum dose was
2.74 Gy with 3D technique compared to 10.7 Gy with
IMRT (p = 0.003) whereas the maximum dose was
27.9 Gy with 3D technique and 30.8 Gy with IMRT.
As shown in Table 4, the mean V10 parameter was
64.8 for 3D-CRT and 95 for IMRT (p = 0.0019) while the
other volumetric parameters (V20 and V30) showed no
statistically significant difference between 3D-CRT and
IMRT.
Despite the higher mean dose delivered to the thyroid
gland by IMRT, no statistically significant differences
were found between NTCP values (p = 0.56) (Table 5).Dose to oesophagus
The mean oesophagus dose was 14.17 Gy with 3D tech-
nique compared to 12.93 Gy with IMRT, while the mini-
mum received dose was 0.84 Gy with 3D technique and
1.67 Gy with IMRT. Maximum doses were 30.52 Gy and
30.2 for 3D and IMRT, respectively. The mean V30 par-
ameter was 6.42 for 3D-CRTand 0.33 for IMRT (p = 0.02)
while the other volumetric parameters showed no statis-
tically significant difference between 3D-CRT and IMRT.
Both for 3D and for IMRT treatment NTCP resulted
negligible for all patients.and IMRT plans
IMRT p-value
71.4 (31.2 – 87.7) <0.001
106.6 (104.2 – 108.7) 0.030
100.0 (99.5 – 100.3) 0.294
100.1 (99.5 – 100.4) 0.049
27.7 (0.02 – 75.7) 0.619
28.8 (28.2 - 29.2) 0.028
Figure 1 Comparison of dose distribution and PTV (red line) coverage of 3D-CRT (A,B) vs IMRT (C,D) plans in coronal (A,C) and axial
(B,D) section.
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The mean spinal cord dose was 11.18 Gy with 3D tech-
nique compared to 9.18 Gy with IMRT, the lowest dose
was 0.21 Gy with 3D technique compared to 0.31 Gy
with IMRT; the maximum dose was 30.2 Gy 3D tech-
nique compared to 19.96 Gy with IMRT (p <0.001).
The mean V20 parameter was 17.8 for 3D-CRT and
7.2 for IMRT (p = 0.02) while the other volumetric para-
meters showed no statistically significant difference be-
tween 3D-CRT and IMRT.
For each patient, the NTCP calculated for spinal cord
resulted statistically significant higher for 3D than for
IMRT treatment (p = 0.004).Dose to heart and coronaries arteries
For the heart, the average dose was equal to 4.25 Gy
with 3D technique compared to 4.21 Gy with IMRT, the
lowest dose was 0.25 Gy with 3D technique compared to
0.26 Gy with IMRT while the highest dose was equal to
24.3 Gy with 3D technique compared with 21.94 Gy
with IMRT, without statistical differences. In particular,
for emergency coronary artery the mean dose was equal
to 9.94 Gy with 3D technique compared to 8.98 Gy with
IMRT (p = 0.77). The statistical comparison of V2, V5,
V10, V20 and V30 between 3D-CRT and IMRT showed
no difference.
Both for 3D and IMRT treatment NTCP resulted neg-
ligible for all patients.Dose to lung
Although the mean lung dose was equal to 6.75 Gy with
3D technique compared to 8.69 Gy with IMRT, no sta-
tistically significant difference was recorded between
these two treatments. The lowest dose was 0.13 Gy with
3D-CRT compared to 0.14 Gy with IMRT whereas the
maximum dose was 31.7 Gy with 3D technique com-
pared to 30.7 Gy with IMRT, without statistically signifi-
cant differences.
Regarding the volumetric parameters, for the left lung
the V5 resulted 28.9 in 3D-CRT group respect to V5 in
IMRT group that resulted 48.1 (p = 0.001), while for the
right lung V5 was 30.3 in 3D-CRT and 44.8 in IMRT
(p = 0.03). Considering the V30, for the left lung it was
0.1 with IMRT respect to 3D-CRT that resulted 4.7
(p = 0.014) and for the right lung the V30 was 0.1 with
IMRT respect to V30 of 2.59 with 3D-CRT (p = 0.017).
No statistically significant differences were recorded for
V10 and V20 parameters.
NTCP values showed no statistically significant differ-
ences, with p = 0.081.
Dose to breast
The mean dose to the breast was 0.97 Gy with 3D tech-
nique compared to 2.32 Gy with IMRT, with a statisti-
cally significant difference (p <0.0017). The lowest dose
was 0.06 with 3D technique compared to 0.3 Gy with
IMRT and the maximum dose was 28.6 Gy with 3D tech-
nique compared to 20.29 Gy with IMRT (p <0.0001).
Table 4 Dose-volume parameters for OAR
3D-CRT IMRT p-value
Thyroid
V10 64.8 95 0.0019
V20 46.4 54.6 0.48
V30 16.2 9.6 0.28
Left Lung
V5 28.9 48.1 0.001
V10 20.5 30.0 0.13
V20 13.2 7.8 0.21
V30 4.7 0.1 0.014
Right Lung
V5 30.3 44.8 0.03
V10 23.2 32.8 0.17
V20 14.7 7.9 0.19
V30 2.59 0.1 0.017
Esophagus
V10 49.7 54.6 0.48
V20 31.1 33.7 0.35
V30 6.42 0.33 0.02
Spinal Cord
V5 56.7 66.2 0.25
V10 41.4 55.9 0.07
V20 17.8 7.2 0.02
V30 4.7 0 0.07
Heart
V2 20 26 0.55
V5 15.8 25.7 0.63
V10 12.9 15.3 0.76
V20 7.6 6.5 0.79
V30 1.4 0.2 0.24
Coronary arteries
V2 50.7 62 0.46
V5 44 52.8 0.57
V10 39.2 44.5 0.72
V20 25.7 23 0.78
V30 6.2 0.94 0.10
Left breast
V5 4.14 20.6 0.018
V10 2.5 13.6 0.035
V20 1.08 0 0.09
V30 0.15 0 0.34
Right breast
V5 3.3 17 0.059
V10 1.7 11 0.07
V20 0.9 0 0.04
V30 0.82 0 0.34
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the mean V5 parameter was 4.14 for 3D-CRT and 20.6
for IMRT (p = 0.018) while the mean V10 was 2.5 for
3D-CRT and 13.6 for IMRT (p = 0.035). The same para-
meters for the right breast was as following: a mean V5
of 3.3 for 3D-CRT and 17 for IMRT (p = 0.059) and a
mean V10 of 1.7 for 3D-CRT and 11 for IMRT (p = 0.07).
No statistically significant differences were recorded for
V20 and V30 parameters for left and right breast.
NTCP resulted comparable both for left and right
breast with p = 0.18 and p = 0.086, respectively.
Discussion
The main question addressed in our study is whether
IFRT IMRT is a suitable technique for the treatment of
supra-diaphragmatic early stage HL patients and if it can
replace IFRT 3DCRT. In our study the PTV coverage
obtained with IMRT was significantly better compared
with 3D-CRT and it depends on IMRT ability to modu-
late the intensity of each radiation beam that resulting
on a high conformal delivery of total dose radiation to
PTV. Our results were similar to those reported by other
authors, who showed that IMRT treatment was superior
to 3DCRT plans regarding the PTV coverage [13-17].
This physical and dosimetric concept can be translated
in a maximization of the actual total delivered dose to
the target volume and therefore with an increased prob-
ability of local control.
The open question is whether IMRT might lead to a
lower dose to the surrounding organs and whether the
rate of late complication could be reduced with IMRT,
in particular lung toxicity and cardiac toxicity. In our
study, IMRT showed an advantage respect to the 3D-
CRT technique for the oesophagus and spinal cord. This
dose reduction could translate in a less acute and late
morbidity. In particular, the NTCP, V20 and maximum
dose for spinal cord is significantly lower for IMRT than
for 3D treatment in every patient. In case of mediastinal
relapse, it could be important to reduce the total dose
delivered to the spinal cord for eventual re-irradiation.
About thyroid, in our study the dose parameters analysis
showed that IMRT is no advantageous respect to 3D-
CRT. When supraclavear and/or neck lymph nodes were
included in the treatment volume, the multi-fields IMRT
arrangement was not able to spare the thyroid glands.
On the contrary, when a 3D-CRT (Antero-Posterior and
Postero-Anterior in particular) was employed, the most
part of thyroid gland was not included in the treatment
fields. The mean actual dose delivered with 3DCRT to
thyroid gland in our patients was 15.25 Gy, statistically
lower than the 21.4 Gy with IMRT. When we considered
the volumetric parameter V10, we showed also a statisti-
cally significant advantage for 3D-CRT respect to IMRT
technique. No difference was recorded respect to NTCP
Table 5 NTCP for OAR
OAR 3D-CRT IMRT p-value
Thyroid 2.98 (0.01 - 6) 3.35 (0.01 - 5.5) 0.56
Lungs 0.2 (0.02 - 0.60) 0.08 (0.02 - 0.40) 0.033
Spinal Cord 0.70 (0.01 - 1.40) 0.17 (0.01 - 1.20) 0.004
Breast 0.6 (0.0.1 - 1.5) 0.82 (0.01 - 1.4) 0.086
Oesophagus <0.0001 <0.0001 -
Heart <0.0001 <0.0001 -
Coronary arteries <0.0001 <0.0001 -
Differences were considered statistically significant at p≤ 0.05.
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term survivors of Hodgkin’s lymphoma have a higher inci-
dence of thyroid abnormalities, including hypothyroidism,
hyperthyroidism and thyroid neoplasms [28]. Thyroid
cancer is the second most common tumor reported
among HL survivor patients. The Late Effect Study Group
reported a 36-fold increased risk of thyroid cancer, with
95% of these cancers developing within the radiation
field [29]. In 461 paediatric HL patients, the 20-year esti-
mated cumulative incidence of hypothyroidism stratified
for radiation dose was 30% in patients who received
21 Gy or less and 61% in patients who received more
than 21 Gy [30]. Thus, it is reasonable that lowering the
radiation dose to thyroid gland could reduce the risk of
late toxicity as hypothyroidism and second cancer. We
reported no difference between 3DCRT and IMRT re-
garding the coronary arteries and heart dose parameters
evaluation, as well as for the NTCP. Although no differ-
ence in the mean dose was reported by Girinsky et al.,
they showed a reduction of V30 with IMRT plan. Other
authors stated that the aim of heart sparing was best
achieved with IMRT although complete elimination of
high dose to some parts of the heart was not possible
with any technique [13, 14, 18]. Therefore, moving from
conventional radiation techniques to IMRT would re-
duce the risk of cardiac morbidity and mortality but the
individual magnitude of clinical benefit is hard to pre-
dict. Moreover the patient anatomy, comorbidity and
pre-existent hearth damage could be important adjunct-
ive risk factors. One of the objectives of using IMRT for
patients with HL is to reduce the radiation dose to the
surrounding lung. No agreement was reached regarding
a correlation between lung toxicity and IMRT in HD
patients. Although a reduction of the mean dose to the
lung with IMRT plans was reported, on the other hand
an increase of V20 using IMRT planning was recorded
in other papers [13, 14, 17]. We showed a reduction of
V30 and of NTCP value using IMRT that reach a statis-
tical significance while the V5 parameter was increased
with IMRT. The relationship between this dose-volume
constraint and the risk of lung toxicity has not been
clearly defined. Moreover, whether low dose to a largevolume is more important than higher dose to a smaller
volume in the development of pneumonitis is unknown.
In this context, the role of IMRT in supra-diaphragmatic
HL patients remains largely unknown owing the concern
that IMRT may deliver a low, yet damaging dose to nor-
mal lung tissue.
Finally, literature data seem uniformly believe that
IMRT technique increases the dose delivered to the
breasts in female patients with HL [13-15, 31]. Also in
our experience, the 3D-CRT offers a more convenient
dose distribution to the breast, in particular to the left
breast, respect to IMRT. The impact of the low dose ra-
diation in a large treated volume of the breasts related
to the IMRT technique should be investigated in a pro-
spective setting [15, 31]. The late occurrence of second
breast cancer in HL survivors is a topic of paramount
importance. In this cohort of patients cumulative abso-
lute risks of breast cancer after 10, 20 and 30 years after
the radiation treatment were 1.4%, 11.1% and 29.0%,
respectively [7]. Dosimetric studies showed IMRT as
superior to 3D-CRT in terms of target coverage, con-
formity, and sparing of normal tissue but concerns has
been raised about its carcinogenic risk [31-34]. It has
been estimated that IMRT may increase the risk of sec-
ond cancer by a factor of 1.2-8 but we must point out
that now we have only dosimetric studies and no clinical
data, given the short follow-up of patients treated with
IMRT so far [28-30]. Other issues that should be con-
sidered are the time and resources required for IMRT
planning. In fact we acknowledge that IMRT is quite a
time consuming and labor-intensive procedure if com-
pared to 3D-CRT (increased time for planning, delinea-
tion, dose delivery and quality assurance).
In our opinion, IMRT can be used in patients with HL
supra-diaphragmatic, showing itself to be superior to
3D-CRT in terms of dose distribution within the target
and reduction of dose to organs at risk, especially lung
and bone marrow. It is worth noting that in the present
study the number of fields used in 3D-CRT planning
were sometimes different. However we believe that this
could have a minimum impact on the target coverage
(since similar average doses were obtained), even if it
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Regarding the dose delivered to thyroid with IMRT tech-
nique, the decision should be made on a case by case
basis. We point out also that in the absence of clinical
data, IMRT should be used with caution in HL women
patients. In conclusion, IMRT is a seducing treatment
option in patients with early stage HL, but a number of
theoretical and practical hurdles remain to be resolved
before it can be used routinely in clinical daily practice
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